Archives
Monthly Archive for: "December, 2022"
Monthly Archive for: "December, 2022"
In the phase II Reactive trial in patients with resected pancreatic cancer, MesoPher demonstrated a statistically significant 2-year Recurrence Free Survival of 60% and an excellent safety profileThe observed safety and statistically significant efficacy are the foundation for further randomized clinical research with MesoPher in pancreatic cancerThe randomized phase II/III DENIM trial in mesothelioma patients was completed but missed its primary endpoint despite MesoPher inducing a robust T-cell response
‘s-Hertogenbosch, the Netherlands; December 12, 2022. Amphera B.V., a late-stage biotechnology company developing MesoPher cell therapy to treat cancer, today reports topline results from both the phase II Reactive trial and the
Read more »